Do alkaline phosphatases have great potential in the diagnosis, prognosis, and treatment of tumors?
Alkaline phosphatase (ALP)
biomarker
bone metastasis
cancer
Journal
Translational cancer research
ISSN: 2219-6803
Titre abrégé: Transl Cancer Res
Pays: China
ID NLM: 101585958
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
received:
11
07
2023
accepted:
22
09
2023
medline:
16
11
2023
pubmed:
16
11
2023
entrez:
16
11
2023
Statut:
ppublish
Résumé
Alkaline phosphatase (ALP) is a group of enzymes that catalyze hydrolysis of phosphate esters at an alkaline pH, resulting in the generation of inorganic phosphate. These enzymes are widely distributed, and their activity is found in various tissues including bone, liver, intestine, and placenta. However, abnormalities in ALP expression and activity have been observed in certain types of cancer. In some cases, elevated serum levels of ALP are observed in patients with liver and bone metastasis. In other cases, increased levels of ALP have been observed in patients with pancreatic and lung cancer. On the other hand, low expression of ALP has also been associated with poor prognosis in patients with certain types of tumors, including colorectal cancer (CRC), breast cancer, and non-small cell lung cancer (NSCLC). In these cases, low ALP activity may be associated with decreased differentiation of cancer cells and increased cancer cell proliferation. Overall, the role of ALP in cancer is complex and context-dependent. This article reviews application progress of ALP in cancer, and we hypothesize that ALP might be a potential tumor biomarker, combined detection of aspartate aminotransferase (AST)/alanine aminotransferase (ALT), bone-specific alkaline phosphatase (BSAP), carbohydrate antigen 19-9 (CA 19-9), lactate dehydrogenase (LDH) and ALP isozymes levels can be used for more accurate diagnosis of a particular tumor. Further research is needed to better understand the mechanisms underlying ALP dysregulation in cancer and to identify potential therapeutic targets.
Identifiants
pubmed: 37969388
doi: 10.21037/tcr-23-1190
pii: tcr-12-10-2932
pmc: PMC10643954
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
2932-2945Informations de copyright
2023 Translational Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1190/coif). The authors have no conflicts of interest to declare.
Références
Gastric Cancer. 2022 Mar;25(2):401-410
pubmed: 34714423
Int J Obes (Lond). 2018 Jun;42(6):1202-1210
pubmed: 29899523
Angew Chem Int Ed Engl. 2020 Oct 5;59(41):18010-18015
pubmed: 32613710
Gastric Cancer. 2019 Jul;22(4):684-691
pubmed: 30417313
F S Sci. 2023 Feb;4(1):30-35
pubmed: 35940575
Epigenetics. 2022 Jan-Feb;17(2):147-160
pubmed: 33797312
Prostate. 2020 Jan;80(1):17-27
pubmed: 31579967
Cancer Cell Int. 2021 Apr 15;21(1):217
pubmed: 33858415
Asian Pac J Cancer Prev. 2021 Jan 01;22(1):131-137
pubmed: 33507690
Cold Spring Harb Protoc. 2020 Aug 3;2020(8):100768
pubmed: 32747588
Mol Clin Oncol. 2021 May;14(5):107
pubmed: 33815795
Med Sci Monit. 2021 Oct 02;27:e931868
pubmed: 34599137
Cancer Res. 1989 Sep 1;49(17):4696-700
pubmed: 2547514
Calcif Tissue Int. 2023 Feb;112(2):233-242
pubmed: 36571614
Sci Rep. 2020 Dec 3;10(1):21180
pubmed: 33273596
Biosens Bioelectron. 2022 Feb 15;198:113826
pubmed: 34891059
Spectrochim Acta A Mol Biomol Spectrosc. 2022 Apr 15;271:120948
pubmed: 35104744
Brain Tumor Pathol. 2020 Apr;37(2):60-68
pubmed: 32367333
BMC Cancer. 2020 Jul 18;20(1):673
pubmed: 32682409
IJU Case Rep. 2022 Mar 26;5(3):179-182
pubmed: 35509789
Transl Androl Urol. 2021 Oct;10(10):3986-3999
pubmed: 34804841
Bioact Mater. 2021 Jul 24;9:120-133
pubmed: 34820560
Hum Reprod. 2022 Jul 30;37(8):1712-1726
pubmed: 35678707
Int J Reprod Biomed. 2022 Jul 06;20(6):433-446
pubmed: 35958959
Clin Nucl Med. 2022 Aug 1;47(8):e521-e528
pubmed: 35543629
Rep Biochem Mol Biol. 2021 Jul;10(2):307-313
pubmed: 34604420
Sci Rep. 2020 Jul 29;10(1):12669
pubmed: 32728117
Galen Med J. 2022 Nov 15;11:e2397
pubmed: 36698694
Oncol Lett. 2023 Mar 03;25(4):154
pubmed: 36936017
Biochem Biophys Rep. 2021 Apr 26;26:101004
pubmed: 33997318
Clin Genitourin Cancer. 2021 Jun;19(3):223-229
pubmed: 33632570
Clin Chim Acta. 2020 Feb;501:198-206
pubmed: 31734146
J Int Med Res. 2020 May;48(5):300060520925644
pubmed: 32425092
Medicine (Baltimore). 2018 Oct;97(40):e12694
pubmed: 30290664
J Endocrinol Invest. 2022 Jan;45(1):125-137
pubmed: 34213743
J Clin Pharmacol. 2021 Oct;61(10):1334-1343
pubmed: 33822385
BMC Musculoskelet Disord. 2022 May 18;23(1):467
pubmed: 35585578
Oncologist. 2018 Jul;23(7):791-797
pubmed: 29700205
Cancer Manag Res. 2020 Mar 18;12:2015-2024
pubmed: 32256109
J Bone Oncol. 2020 Nov 05;26:100337
pubmed: 33240786
BMC Cancer. 2019 Aug 7;19(1):785
pubmed: 31391026
Clin Chem Lab Med. 2017 Jun 27;55(7):e146-e149
pubmed: 27845880
Lancet Gastroenterol Hepatol. 2022 Sep;7(9):843-850
pubmed: 35617978
Eur J Cancer. 2020 Apr;129:117-122
pubmed: 32151941
Purinergic Signal. 2019 Mar;15(1):95-105
pubmed: 30644036
J Bone Miner Res. 2022 Oct;37(10):2033-2043
pubmed: 36054139
Oncology. 2021;99(1):23-31
pubmed: 32906115
Stem Cell Res Ther. 2021 Jul 22;12(1):415
pubmed: 34294121
FASEB J. 2019 Nov;33(11):11884-11893
pubmed: 31366234
Arch Pharm (Weinheim). 2020 May;353(5):e2000011
pubmed: 32128876
JCI Insight. 2021 May 10;6(9):
pubmed: 33755595
BMJ Open. 2020 Mar 8;10(3):e033532
pubmed: 32152162
Front Endocrinol (Lausanne). 2022 Feb 22;13:826660
pubmed: 35273570
Placenta. 2023 Feb;132:32-37
pubmed: 36623417
Br J Cancer. 2005 May 23;92(10):1934-41
pubmed: 15856041
Am J Physiol Renal Physiol. 2010 Sep;299(3):F674-80
pubmed: 20610533
Front Nutr. 2020 Nov 16;7:585306
pubmed: 33304918
Eur Urol. 2022 Apr;81(4):364-372
pubmed: 34953600
J Toxicol Sci. 2011 Apr;36(2):211-9
pubmed: 21467748
Cell Signal. 2022 Nov;99:110404
pubmed: 35835331
J Neurooncol. 2021 Apr;152(2):405-413
pubmed: 33630256
Int J Biol Markers. 2023 Mar;38(1):25-36
pubmed: 36775971
Science. 2019 Jun 21;364(6446):1156-1162
pubmed: 31221853
J Orthod. 2018 Mar;45(1):4-10
pubmed: 29281939
Clin Respir J. 2021 May;15(5):540-549
pubmed: 33565707
BMC Cancer. 2020 Jun 9;20(1):541
pubmed: 32517802
Lab Chip. 2019 Jan 15;19(2):335-342
pubmed: 30566170
Cancers (Basel). 2021 Dec 06;13(23):
pubmed: 34885242
Med Clin North Am. 2018 Mar;102(2):251-264
pubmed: 29406056
PLoS One. 2020 Sep 17;15(9):e0238954
pubmed: 32941505
Nutr Res. 2018 May;53:23-31
pubmed: 29804586
Onco Targets Ther. 2019 Jul 02;12:5241-5249
pubmed: 31303770
Nanoscale. 2019 Mar 28;11(13):6307-6314
pubmed: 30882834
Clin Nephrol. 2021 Aug;96(2):96-104
pubmed: 34042581
Int J Occup Environ Med. 2020 Jul;11(3):140-147
pubmed: 32683426
Urolithiasis. 2022 Dec 26;51(1):23
pubmed: 36571714
Mol Med Rep. 2018 Jan;17(1):1537-1544
pubmed: 29257226
Future Oncol. 2021 Apr;17(12):1507-1518
pubmed: 33626926
PLoS One. 2022 May 26;17(5):e0268843
pubmed: 35617260
Rocz Panstw Zakl Hig. 2022;73(2):215-220
pubmed: 35748566
Saudi J Biol Sci. 2022 Aug;29(8):103340
pubmed: 35770272
Cells. 2021 Nov 28;10(12):
pubmed: 34943845
EPMA J. 2020 Nov 18;11(4):565-579
pubmed: 33240450
Int J Clin Oncol. 2020 Feb;25(2):247-257
pubmed: 31768692
Breast Cancer (Auckl). 2019 Feb 22;13:1178223419830978
pubmed: 30828246
Biol Trace Elem Res. 2018 Dec;186(2):413-429
pubmed: 29651733
Metab Brain Dis. 2019 Feb;34(1):3-19
pubmed: 30284677
Cell J. 2021 Nov;23(6):717-721
pubmed: 34939766
Research (Wash D C). 2019 Dec 3;2019:4803624
pubmed: 31912037
Gastroenterology. 2021 Mar;160(4):1373-1383.e6
pubmed: 33333055
Abdom Radiol (NY). 2020 Nov;45(11):3789-3799
pubmed: 32440900
J Pathol Clin Res. 2021 Nov;7(6):577-589
pubmed: 34363325
Nutrients. 2022 May 19;14(10):
pubmed: 35631265